Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
AACR, abstract, accredited, advocated, Amgen, AMP, benchmark, benchmarking, branch, broaden, broader, bystander, Chevron, Chinese, claudin, climate, cluster, companion, composed, confirmatory, Cosmetic, costimulation, crystallizable, cytotoxic, cytotoxicity, deprioritized, deruxtecan, displaying, East, EMPOWHER, ESG, explicit, FR, Gallagher, gamma, glycosylphosphatidylinositol, guided, heterogeneity, highest, highlighted, histopathological, hypothetical, Imputed, induction, inhibition, inoperable, interrogation, Jeffrey, Jersey, killing, library, ligand, logistical, MAA, maximizing, mediated, medium, Middle, NMPA, nongovernmental, paused, pembrolizumab, peripheral, persist, phosphate, pilot, placement, point, predecessor, proliferation, ready, Redwood, regression, retaliation, reveal, rolling, Sanofi, SCLC, screening, serial, session, short, silenced, small, Smith, spheroid, stochastic, successor, supplement, TCE, technique, translating, translation, undermine, unencumbered, valency, Vice, vitro, vivo, wildtype, York
Removed:
accretion, accrue, adequacy, affiliate, ALX, amendment, antitumor, article, Atreca, attest, attestation, Blue, CI, colorectal, committed, compensatory, confirming, deep, deeper, depleted, derived, determinable, detrimental, disposition, docetaxel, eighteen, ESPP, evorpacept, exceeding, exemption, expressing, filer, force, fulvestrant, FZE, growing, hormone, Ibrance, identification, iii, intent, iv, Japanese, Korea, LEO, liquid, long, manageable, marketability, median, method, Middletown, mission, monotherapy, morale, movement, multicenter, NE, nominating, noted, opted, palbociclib, pancreatic, parent, passive, Pfizer, Pharma, pretreated, pursuing, readily, recovering, recovery, redeem, reevaluated, referenced, rejection, reluctant, renewed, requisite, reside, restatement, retail, retraction, reversed, satisfied, sequester, South, subjectively, sublicense, sunset, taxable, terminating, Territory, tislelizumab, transitional, unanimously, undertaken, undervalued, Unrealized, vi, ZBI, ZZI
Filing tables
Filing exhibits
Related press release
Associated Zymeworks transcripts
Zymeworks similar filings
Filing view
External links
Exhibit 32.2
SECTION 906 CERTIFICATION
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) in connection with the Quarterly Report on Form 10-Q of Zymeworks Inc. for the quarterly period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer hereby certifies, to such officer’s knowledge, that:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Zymeworks Inc.
| /s/ Kenneth Galbraith | ||||||||
| Name: | Kenneth Galbraith | |||||||
| Title: | Interim Chief Financial Officer | |||||||
| Date: | May 2, 2024 | |||||||
This certification accompanies the Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed “filed” by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.